T1	Participants 763 828	36 patients in the control group, 14 with positive urine cytology
T2	Participants 881 928	22 patients with negative cytology (P = 0.004).
T3	Participants 1138 1230	72 patients in the Pirarubicin Monotherapy Study Group trial, 31 had positive urine cytology
